Experimental Alzheimer's Drug Shows Promise

Tuesday, October 4th, 2022 -- 10:00 AM

(Bob Hague, WRN) The experimental drug Lecanemab is showing promise in treating Alzheimer's disease. That’s according to Tim Harrington with the Wisconsin chapter of the Alzheimer's Association.

Reports say it can slow the rate of cognitive decline by 27-percent. "In slowing the rate of cognitive decline or slowing down the progression of disease, really what it does is allows for a better quality of life for those living with Alzheimer's and their families and allows them to be able to remain independent for a longer period of time.”

Harrington says Lecanemab is being tested. "They're hoping that by early next year, they're at that point where the FDA has made a decision. It's only been tested in people with mild cognitive impairment due to Alzheimer's or very early stage Alzheimer's, so if it is approved, those are the only people that would be approved to get it."

While it's promising that this drug appears to be able to slow down the progression of Alzheimer's, Harrington stresses that it's not a cure.

Feel free to contact us with questions and/or comments.